A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
about
Systemic manifestations of hepatitis C infectionInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseKASL clinical practice guidelines: management of hepatitis CExtrahepatic manifestations of chronic hepatitis C virus infectionChronic hepatitis C: This and the new era of treatmentStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesImpact of new treatment options for hepatitis C virus infection in liver transplantationHIV and hepatitis C virus infection in the United States: whom and how to testThe Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current ChallengesA comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014Hepatitis C virus: Virology, diagnosis and treatmentHepatitis C screeningPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesPredictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3Reinventing HCV Treatment: Past and Future Perspectives.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeTreatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort.All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.Frontiers in the treatment of hepatitis C virus infection.High rates of early treatment discontinuation in hepatitis C-infected US veterans.Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingHepatitis C in Argentina: epidemiology and treatment.Hepatitis C Virus and Liver Transplantation.Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Current and future therapies for hepatitis C virus infection.Hepatitis C virus infection in the human immunodeficiency virus infected patient.Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionSystematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.Mortality among British Columbians testing for hepatitis C antibody.Current and future disease progression of the chronic HCV population in the United States.Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis
P2860
Q26746040-8C8F6862-F960-4B69-89CC-CBDBEB6B12B7Q26746563-C23A55BB-3C36-4E6A-935F-013BD3491E8AQ26752433-703A388B-942B-4FC8-87BE-610968704044Q26752471-6E7D7658-6917-47FD-A059-ADA27D2E5E57Q26767084-F196F6BD-72B3-4924-9AE9-4490FF8FA75AQ26775011-D2C94A85-4AEB-409E-9DA4-F59CE3052F9BQ26777086-9B2056AA-CB82-43A2-BB47-B76FD9B9BF9FQ26782017-B86363E6-84A8-4FED-8A46-C49BE46191D3Q26996736-2DAC149D-B4BE-496C-B3BD-B5B6D23B1802Q28081108-60733822-AEC8-4295-90CF-127DA0AEFF38Q28081137-811A0C2F-ECEC-4F7E-889D-D8255B6740D9Q28082000-467C2069-61DD-4395-BE46-5029E7B6AA3EQ28083429-6278BE47-6257-4E6A-8D99-4630643B8B2EQ28272678-FB51F4F2-C9D1-45FF-8A13-3AA81223E976Q28488762-1BE6627D-173B-4E0D-A295-B57783FD769AQ28543090-3790A535-C059-4B9F-8211-86B0CE7D5A92Q28732828-05946C1F-B5AB-452D-84A3-8A8D9DEAC9A8Q30241881-F32A97B3-6B0B-447A-B44C-4DA442B9959DQ30453975-455FD9D7-CE99-4358-9850-1D9B549123F8Q31012317-B3853B17-4045-4F06-804F-30EF34DA1970Q31160142-104A9805-89BE-4266-84F9-62CB699EFB11Q33411348-86D8FCB6-9125-42DD-99A5-D4DAD122DD06Q33413353-8BFD686D-85E4-46BF-8C46-16D8FF2454C4Q33571517-D6EB9EAD-95DC-4E20-98A2-EB0A7675D444Q33574602-CA1EC2BC-1052-4819-B09E-F3D5F6505F3CQ33646482-43509C36-2739-4A76-BDD0-697504DDCC29Q33706886-877270DC-57DC-4C4C-A6B9-D6B6749F29B0Q33717116-B167A995-E57F-4551-A69C-AFCCDF44F7BDQ33807745-48AB027A-0570-4244-824F-97747893BBF7Q33837518-B51F62F5-23EA-4D32-9C33-34AE1C293AB9Q33853664-DB5298FC-675A-4F59-BE66-20D1BA66D3A4Q34036762-C631F580-4CE2-4CF6-A7EA-9BEA41800C3DQ34168504-D87BAEBB-A636-4200-B8B2-A036F409CB49Q34403692-8358E13B-C809-4064-B05C-78F2958ECBF6Q34506788-5499A114-444E-4675-B14E-3732F212E757Q34522481-526BB275-8502-45FD-B2E9-20A27A24A61EQ34524584-10D4590D-5CC7-4137-9680-477B4389A051Q34645221-9E487AE4-8561-4C01-AD77-62A85C165D84Q34737843-4148ACF2-CD4E-4D84-8872-1244A20B9949Q34926607-915A6988-2EEC-4633-AF34-00852720132D
P2860
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A sustained virologic response ...... in patients with hepatitis C.
@en
A sustained virologic response ...... in patients with hepatitis C.
@nl
type
label
A sustained virologic response ...... in patients with hepatitis C.
@en
A sustained virologic response ...... in patients with hepatitis C.
@nl
prefLabel
A sustained virologic response ...... in patients with hepatitis C.
@en
A sustained virologic response ...... in patients with hepatitis C.
@nl
P2093
P1476
A sustained virologic response ...... in patients with hepatitis C.
@en
P2093
Barbara R Phillips
Derek B Boothroyd
James Halloran
Larry A Mole
Pamela Belperio
P304
509-516.e1
P356
10.1016/J.CGH.2011.03.004
P407
P577
2011-03-11T00:00:00Z